Oren Gilad
Chief Executive Officer at APREA THERAPEUTICS, INC.
Net worth: 2 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Peters | M | 61 | 4 years | |
| John Hamill | M | 60 | 1 years | |
| Michael Grissinger | M | 70 |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 6 years |
| Bernd Seizinger | M | 67 | 9 years | |
| John Henneman | M | 62 | 5 years | |
| Rifat Pamukcu | M | 66 | 2 years | |
| Bernard Rudnick | M | - |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 9 years |
| Marc Duey | M | 68 | 2 years | |
| Gabriela Gruia | M | 67 | 1 years | |
| Zeev Weiss | M | 62 | 2 years | |
| Jeffrey Dayno | M | 66 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 8 years |
| Jean Bizzari | M | 69 | 1 years | |
| Benjamin R. Cowen | M | 63 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Schade | M | 63 | 7 years | |
| Michael Kelly | M | 67 | 2 years | |
| Scott Coiante | M | 57 | 4 years | |
| Fouad Namouni | M | 55 | 2 years | |
| Gregory Korbel | M | 48 | 7 years | |
| Lars Abrahmsén | M | 66 | 8 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 19 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Oren Gilad
- Personal Network
